NCT00699842View on ClinicalTrials.gov

A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

January 31, 2011

Study Completion Date

May 31, 2012

Conditions
Myelodysplastic SyndromeMDSLow to Intermediate-1 MDSNon-deletion 5q
Interventions
DRUG

Lenalidomide

"Dose Level Lenalidomide Schedule~1. 15mg/day for d1-21 out of 28 days~2. 20mg/day for d1-21 out of 28 days~3. 25mg/day for d1-21 out of 28 days"

Trial Locations (2)

19107

Thomas Jefferson University, Philadelphia

19130

Associates in Hematology-Oncology, PC, Chester

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER

NCT00699842 - A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients | Biotech Hunter | Biotech Hunter